IBM stock climbs as Jefferies turns bullish and lifts target to $360

IBM stock climbs as Jefferies turns bullish and lifts target to $360

New York, Jan 5, 2026, 14:09 (EST) — Regular session

  • IBM shares rose on fresh bullish calls from Jefferies and RBC Capital.
  • Jefferies upgraded the stock to Buy and lifted its price target to $360.
  • Investors are looking ahead to IBM’s Jan. 28 earnings update for 2026 demand signals.

International Business Machines (IBM.N) shares rose 1.6% to $296.24 in afternoon trading on Monday, after Jefferies upgraded the stock and RBC Capital raised its price target. The shares traded between $293.00 and $299.18 on the day.

The upbeat calls land as Wall Street starts to reset 2026 expectations for enterprise software and spending on artificial intelligence tools. For IBM, the next test is whether its software and hybrid-cloud businesses can keep growing fast enough to justify a premium multiple.

Jefferies upgraded IBM to Buy from Hold and raised its price target — an analyst’s estimate of where a stock could trade over the next 12 months — to $360 from $300. The broker said it is repositioning its software coverage for 2026, arguing that infrastructure software should hold up better than application software early in the year. TipRanks

Jefferies analyst Brent Thill wrote: “These moves strengthen IBM’s hybrid cloud and data platform capabilities, creating cross-sell opportunities and expanding its open-source monetization muscle.” Investors

RBC Capital also lifted its price target on IBM to $350 from $300 and kept an Outperform rating, meaning it expects the stock to beat the broader market. The firm said enterprise spending appears to be stabilizing, with generative AI — systems that produce text, code or images — pushing more experimentation even as management teams stay cautious in early-2026 guidance. TipRanks

IBM outperformed a broadly higher market on Monday. The S&P 500 proxy SPY rose about 0.8% and the Nasdaq proxy QQQ gained about 0.9%, while Oracle (ORCL.N) fell 1.0% and Adobe (ADBE.O) slipped 0.2%.

The analyst optimism also leans on IBM’s deal-led software push. IBM last month agreed to buy Confluent for $11 billion in cash, a transaction it said is expected to close by mid-2026, adding real-time data-streaming capabilities aimed at enterprise AI deployments. IBM Newsroom

From a chart perspective, IBM is still below its 52-week high of $324.90 and well above its 52-week low of $214.50, leaving the round-number $300 level in focus for short-term traders. Investing

But the upside case depends on execution. If corporate IT budgets soften, or if AI projects fail to convert into repeatable software revenue, IBM’s software growth narrative could lose traction; regulatory delays or integration challenges around the Confluent deal would add another overhang.

Next up is IBM’s fourth-quarter earnings announcement, scheduled for Jan. 28 (preliminary date). Investors will be watching for 2026 demand commentary, software growth trends and any timeline updates on major integration work tied to pending acquisitions. Ibm

Stock Market Today

  • Pool price weakness hints at valuation gap, DCF shows ~22% discount
    January 7, 2026, 9:44 PM EST. Pool trades at $237.01, with a year-to-date and 12-month performance of -25.8%. A Discounted Cash Flow (DCF) model-using a two-stage Free Cash Flow to Equity approach-values the stock at about $302.36 per share. That yields roughly a 21.6% discount to the current price, signaling the shares may be undervalued on cash flows. The last twelve months' Free Cash Flow was about $396.6 million; projections extend to $482.0 million in 2028, then rise through 2035. The stock trades at a P/E ratio of 21.53x, above the industry average of 17.70x but below the peer group average of 42.71x. The picture: valuation suggests a potential opportunity, though risk remains to broader earnings trends and market sentiment.
D-Wave Quantum stock jumps nearly 10% as options bets build ahead of CES 2026
Previous Story

D-Wave Quantum stock jumps nearly 10% as options bets build ahead of CES 2026

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus
Next Story

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Go toTop